ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.
Latest news
ImCheck to Present Updated ICT01 Data with Unprecedented High Rates of Complete Remission in AML at the AACR Annual Meeting 2025
Science & Medicine
Read more Replay of the Leukemia & Lymphoma Society's TAP event: Dr. Stephan Braun, our CMO, highlights ICT01 data presented at ASH 2024
Science & Medicine
Read more ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Meeting Annual Meeting
Science & Medicine
Read more STAY IN TOUCH WITH OUR LATEST NEWS
Subscribe to receive our press releases and related news